What’s the official name and why is Pexidartinib sold under a brand?
Pexidartinib is marketed as Turalstat. It’s a small‑molecule inhibitor of colony‑stimulating factor‑1 receptor (CSF‑1R) used to treat tenosynovial giant cell tumor (TGCT) that cannot be fully removed surgically. The brand name is the same across most markets because the drug is regulated under a single FDA‑approved label.
How do I start and adjust the dose?
Begin with 200 mg orally twice daily, separated by at least 30 minutes. After at least 30 days, you may increase to 400 mg twice daily if tolerated and if the benefit outweighs the risk. The maximum daily dose is 400 mg twice daily; doses above this are not recommended.
What are the key warnings I need to be aware of?
The label flags liver toxicity as a serious risk. Elevated transaminases (AST/ALT) or bilirubin, or clinical signs of hepatic dysfunction, warrant dose interruption or discontinuation. The drug carries a black‑box warning for severe, reversible, potentially fatal liver injury.
What side effects are most common?
Patients most often report nausea, fatigue, diarrhea, headache, and dizziness. Severe rash, edema, and arthralgia can occur but are less frequent. Close monitoring of liver enzymes and regular lab checks are mandatory.
Can Pexidartinib mix safely with other drugs?
It is metabolized primarily by CYP3A4/5. Strong CYP3A inhibitors (e.g., ketoconazole) or inducers (e.g., rifampin) can alter plasma levels, so dose adjustments may be needed. Avoid concomitant use with other hepatotoxic agents whenever possible.
What monitoring is required while on treatment?
Baseline liver function tests (LFTs) are required. Check LFTs at 2, 4, and 8 weeks, then every 4 weeks while on therapy. If AST or ALT rise above 3× upper limit of normal (ULN), interrupt dosing until levels fall below 1.5× ULN, then resume at the same dose.
When should therapy be stopped or interrupted?
Stop immediately if you develop signs of acute liver failure: jaundice, confusion, or coagulopathy. The drug is also contraindicated if the patient has a history of severe liver disease.
Which patient groups need special attention?
Pregnancy: Pexidartinib is category X; it can cause fetal harm, so effective contraception is essential for both genders. Pediatric and geriatric data are limited; use with caution in the elderly and monitor liver function closely.
How do I store and handle the medication?
Keep the tablets at room temperature (15–30 °C) in a dry place. Protect from moisture and do not exceed the expiration date.
Who makes Pexidartinib and when was it approved?
The drug is produced by Horizon Therapeutics and received FDA approval in 2019 for TGCT. It is also approved by the European Medicines Agency under the same brand name.
When will the patent on Pexidartinib expire?
The original U.S. patent (US 20120037838A1) covering the therapeutic composition was filed in 2011. The patent term was extended and is expected to expire in 2028, giving the manufacturer exclusivity for at least nine years post‑approval. This timeline may affect the entry of biosimilars or generics. [1]
Is there a biosimilar or alternative on the market?
No approved biosimilar exists yet, partly because the drug is small‑molecule, not a biologic. Alternatives include surgical management and other CSF‑1R inhibitors in clinical trials, but none have the same approval status.
What about the drug’s mechanism and its impact on tumor cells?
Pexidartinib blocks CSF‑1R signaling, reducing macrophage infiltration and tumor proliferation. This leads to tumor shrinkage or reduced joint swelling in TGCT patients, as demonstrated in phase III trials.
Can I expect price changes or insurance coverage details?
Coverage varies by insurer. Some plans cover it under the specialty drug tier, often requiring prior authorization. The manufacturer offers a patient assistance program for those who qualify.
Where can I find the full, up‑to‑date label?
The official FDA label is available on the FDA’s website and can be downloaded in PDF format for detailed dosing, safety, and prescribing information.
Sources
[1] https://www.drugpatentwatch.com/